Brand:
Dragon Pharma, Europe
Manufacturer:
Dragon Pharma, Europe
Dosage Info:
<div class="tab-pane fade" id="offer-tabbody--dosage-and-usage" role="tabpanel">
<section class="tab-panel" id="panel-usage">
<h2>Dosage & Usage Guidelines</h2>
<p>PT-141 is administered via subcutaneous injection. The standard dose is 1–2 mg taken approximately 2 to 4 hours before sexual activity. Due to its fast absorption, it's recommended to begin with 1 mg and increase only if needed, based on personal tolerance and response.</p>
<h3>Example PT-141 Cycle</h3>
<p><strong>Weeks 1–4:</strong> 1.25 mg, 2–3 times per week as needed<br/> <strong>Maintenance:</strong> 1 mg as required prior to intimacy</p>
<p>PT-141 may be safely combined with <a href="https://www.dragonpharma.net/peptides-414/ipamorelin-45654">Ipamorelin</a> or <a href="https://www.dragonpharma.net/sexual-health-415/cialis-3411">Cialis</a> for enhanced performance benefits. Explore our <a href="/">verified Dragon Pharma supplier</a> catalog for more stacking options.</p>
<h3>Possible Side Effects</h3>
<p>Most users tolerate PT-141 well, though initial doses can cause mild effects such as:</p>
<ul>
<li>Nausea or flushing</li>
<li>Facial redness or warmth</li>
<li>Headache or dizziness</li>
</ul>
<p>These effects are temporary and can often be reduced by injecting in the evening or on an empty stomach.</p>
<h3>Post-Cycle Therapy (PCT)</h3>
<p>Since PT-141 does not affect natural testosterone or estrogen levels, it does not require post-cycle therapy. Users may cycle it continuously or intermittently based on desired results and sexual frequency.</p>
<h3>Why Choose PT-141 by Dragon Pharma?</h3>
<p>Dragon Pharma's PT-141 stands out for its purity, lab-tested quality, and performance-driven results. Whether you're looking to enhance intimacy, address erectile challenges, or reignite libido, PT-141 is a proven non-hormonal solution backed by clinical data.</p>
<p>Explore more premium Dragon Pharma gear for advanced performance, peptide cycles, and hormone support.</p>
</section>
</div>
Technical Details
Peptide Type
Synthetic Cyclic Heptapeptide
Peptide Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Peptide Length
7 Amino-Acid Residues
Structural Form
Lactam-Bridged Cyclic Peptide
Structural Origin
Deamidated Melanotan II Metabolite
Molecular Formula
C₅₀H₆₈N₁₄O₁₀
Molecular Weight
1025.2 g/mol
Receptor Profile
Melanocortin Receptor Agonist
Receptor Activity
MC1R, MC3R, MC4R & MC5R
